

5 June 2023

**Cizzle Biotechnology Holdings Plc**

(“Cizzle Biotechnology”, “Cizzle” or the “Company”)

**Posting of Annual Report and Notice of AGM**

Cizzle Biotechnology, the UK-based diagnostics developer, is pleased to announce that copies of the annual report and accounts for the year ended 31 December 2022, together with the notice of Annual General Meeting (“AGM”), have been sent to shareholders and are available for viewing on the Company's website at <https://cizzlebiotechnology.com>.

The AGM of Cizzle Biotechnology will be held at 11.00 a.m. BST on 28 June 2023 at the offices of Shakespeare Martineau LLP, 6<sup>th</sup> Floor, 60 Gracechurch Street, London, EC3V 0HR.

**Enquiries:**

**Cizzle Biotechnology Holdings plc**  
Allan Syms (Executive Chairman)

**Via IFC Advisory**

**Allenby Capital Limited**  
John Depasquale  
Alex Brearley

**+44(0) 20 33285656**

**Novum Securities Limited**  
Colin Rowbury  
Jon Bellis

**+44(0) 20 7399 9400**

**IFC Advisory Limited**  
Tim Metcalfe  
Florence Chandler

**+44(0) 20 3934 6630**  
**cizzle@investor-focus.co.uk**

**About Cizzle Biotechnology**

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com> You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.